Hong Kong Stock Market Movement | Innophora Bio-B (09606) Rises Over 4% in Early Trading Session; Plans Share Buyback of Up to USD 40 Million and Receives Share Purchase by Founder Zhu Zhongyuan

In early trading, InnoCare Pharma-B (09606.HK) rose more than 4%. As of the time of writing, it was up 2.6% at HK$220, with a trading volume of HK$22.3895 million.

Zhitong Finance09:33

Innovent Biologics-B (09606) plans to repurchase up to USD 40 million of its shares, and founder Zhu Zhongyuan intends to purchase no more than USD 5 million worth of shares.

InnoCare Pharma-B (09606) announced that the Board intends to exercise the authority granted by shareholders at the company's annual general meeting held on June 20, 2025, to repurchase shares of the company in the open market at an appropriate time. The share repurchase program will utilize up to USD 40 million for such repurchases. The company will fund the repurchases using its internal resources and intends to hold the repurchased shares as treasury shares.

Zhitong FinanceMay 19 22:10

HKEX Announcements Insight | JD.com-SW Reports Steady Revenue Growth and Record High Retail Profit in Q1, with Significant Increase in R&D Investment

JD.com-SW achieved steady revenue growth in the first quarter, with retail profitability reaching a new high and significant growth in R&D investment; Pop Mart's overall revenue increased by 75%-80% year-on-year in the first quarter.

Zhitong FinanceMay 13 09:05

Yingen Bio-B (09606): Notice of Exercise of DB-1311/BNT324 Cost and Profit/Loss Sharing Option

Duality Bio-B (09606) announced that, as of May 12, 2026, Hong Kong Time (“Exercise Date”), the company has issued a written notice to BioNTech SE (“BioNTech”), whose shares are listed on the Nasdaq Stock Market (Nasdaq Code: BNTX), to exercise the exclusive cost and profit/loss sharing option for the U.S. market regarding DB-1311/BNT324 (“DB-1311/BNT324 Cost and Profit/Loss Sharing Option”) granted under the License and Collaboration Agreement (“Collaboration Agreement”) entered into between the company and BioNTech on March 31, 2023, concerning DB-1311.

Zhitong FinanceMay 13 06:35

Duality Biotherapeutics Wins Shareholder Approval for RMB Share Issue and Sci-Tech Board Listing

TipRanksApr 29 20:06

DUALITYBIO-B: 2025 Annual Report

HKEXApr 26 19:15 · Announcements